TAI'AN, Shandong, China, March 23
/PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc.
(Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the
leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"),
operating through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co. Ltd. ("Taibang") and
Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin") and its
equity investment in Xi'an Huitian Blood Products Co., Ltd.
("Huitian"), today reported financial results for the fourth
quarter and year ended December 31,
2009.
Fourth Quarter 2009 Highlights
-- Revenues increased 185.6% year-over-year to $37.6 million
-- Excluding Dalin, revenues rose 46.7% year-over-year to $19.3 million or
51.4% of total revenue
-- Gross profit increased 208.6% year-over-year to $27.3 million,
representing a gross margin of 72.7% as compared to 67.2% a year ago
-- Operating income grew 342.3% year-over-year to $20.8 million,
representing an operating margin of 55.2%
-- GAAP net loss attributable to controlling interest was $3.8 million, or
$0.17 per share, including a $14.7 million charge related to change in
the fair value of derivative liabilities
-- Non-GAAP adjusted net income was $11.1 million or $0.44 per diluted
share, a 242.4% increase from $3.2 million or $0.15 per diluted share
in the fourth quarter of 2008
-- The Company's common stock began trading on the NASDAQ Global Market on
December 2, 2009
"With our successful integration of Dalin, China Biologic
achieved record top and bottom line results and significant growth
in fiscal 2009, said Mr. Chao Ming
Zhao, Chief Executive Officer of China Biologic. "In
addition, we believe that the successful implementation of the
Company's strategic marketing efforts has attracted more donors to
our plasma collection centers and has resulted in an increase in
our overall collection volume. With a continued shortage of plasma
supply, the Company has continued to work to enhance our production
plans and increase our output and we have been able to maximize our
yield per unit of plasma collected to realize a higher profit
margin. Fiscal 2009 was also a special year for us and our
shareholders as the Company's common stock began trading on the
NASDAQ Global Market.
Full-Year 2009 Highlights
-- Revenues increased 154.5% year-over-year to a record $119.0 million,
exceeding our guidance of $90 to $100 million
-- Excluding the acquisition of Dalin, revenues grew 43.1 % year-over-year
to $66.9 million
-- Gross profit rose 164.1% to $86.4 million, representing a gross margin
of 72.6% as compared to 70.0% a year ago
-- Operating income increased 201.8%, to $61.4 million, representing an
operating margin of 51.6%
-- GAAP net income attributable to controlling interest was $1.3 million,
or $0.07 per diluted share, including a $29.6 million charge related to
change in the fair value of derivative liabilities
-- Non-GAAP adjusted net income was $31.3 million or $1.38 per diluted
share, a 135.0% increase from $13.3 million or $0.62 per diluted share
in 2008
During the full year 2009, the Company achieved the following
key milestones:
-- Closed the acquisition of 90% interest in Dalin, and its 54% majority-
owned operating subsidiary, Qianfeng Biological Products Co., Ltd.
("Qianfeng"), one of the largest plasma-based biopharmaceutical
companies in China located in Guiyang, Guizhou Province. Starting from
January 1, 2009, Qianfeng's operations were consolidated into the
Company's financial results.
-- Completed the purchase of 35% equity interest in Xi'an Huitian Blood
Products Co, Ltd ("Huitian"), a plasma-based biopharmaceutical company
in Xi'an, Shaanxi Province
-- Qianfeng received renewal of SFDA certification, valid until September
2014, of compliance with Good Manufacturing Practices ("GMP") for its
production facility with 400 tons of annual production capacity for
plasma-based products.
-- China Biologic was named to Forbes Magazine's Fifth Annual List of
Asia's "200 Best Under a Billion" for the year 2009. To assemble its
Best Under a Billion for the Asia-Pacific region, Forbes considered
only listed entities with sales under $1 billion, that have posted
solid top and bottom-line gains, and appear to be headed for more.
Fourth Quarter 2009 Results
For the three months ended December 31,
2009, total revenues reached a record $37.6 million, up 185.6% from the same period a
year ago. Excluding revenues from Dalin, which was acquired in
January 2009, revenues rose 46.7% to
$19.3 million from $13.2 million a year ago. The strong organic
growth was partly attributable to increased demand for the Human
immunoglobulin for intravenous injection product ("IVIG") product
ahead of potential price increase in 2010.
Gross profit for the fourth quarter 2009 was $27.3 million, up 208.6% from $8.9 million in the comparable period a year ago.
Gross margin also increased to 72.7% from 67.2% year-over-year. The
gross profit and margin increases were primarily attributable to
the consolidation of Dalin and price increases implemented during
the year.
Operating expenses increased 58.1% year-over-year to
$6.6 million, primarily reflecting
consolidation of Dalin in the 2009 quarter. Income from operations
for the period was $20.8 million, a
342.3% increase from $4.7 million a
year ago.
Income taxes increased to $3.0
million from $0.2 million,
primarily reflecting a higher effective tax rate of 61.7% as
compared to 3.7% in the year ago quarter. The higher effective tax
rate was due to non-cash expenses incurred in 2009 that are not
deductible under PRC tax law.
GAAP net loss attributable to controlling interest for was
$3.8 million, or $0.17 per diluted share, and included a
$14.7 million charge related to
change in fair value of derivative liabilities, as compared to net
income of $3.2 million, or
$0.15 per diluted share, in the year
ago quarter.
Excluding non-cash employee compensation expenses, change in the
fair value of derivative liabilities and adding back interest
related to the convertible notes under the if-converted method,
non-GAAP adjusted net income for the three months ended
December 31, 2009 was $11.1 million, or $0.44 per diluted share, up 242.4% from
$3.2 million or $0.15 per diluted share in the year ago
quarter.
Full Year 2009 Results
Revenues for the full year 2009 increased 154.5% to a record
$119.0 million from $46.8 million in 2008. The increase in revenues
is primarily attributable to the consolidation of Dalin, which was
acquired in April 2009, beginning
January 2009. During 2009, Dalin
accounted for $52.1 million in
revenues, or 43.8% of total revenues. Excluding Dalin, 2009 base
revenues grew 43.1% year-over-year to $66.9
million from $46.8 million.
Growth in base revenue was primarily due to increase in the prices
of plasma-based products, higher sales volume and a modest increase
related to foreign exchange translation.
Human albumin product revenues rose 118.9% year-over-year to
$59.2 million, accounting for 49.7%
of sales in 2009, as compared to 57.8% in 2008. Revenue growth
reflected volume increase of 117.8% and an average selling price
(ASP) increase of 0.5%. IVIG revenues grew 324.4% to $43.7 million in 2009 and represented 36.8% of
total revenues, as compared to 22.0% of revenues in 2008. Increase
in human immunoglobulin for intravenous injection revenues included
sales volume and ASP increases of 293.4% and 7.9%, respectively.
Sales of the human tetanus immunoglobulin product rose 76.9% to
$2.6 million, contributing 2.2% of
total revenues as compared to 3.1% in 2008. Sales volume and ASP
for human tetanus immunoglobulin increased 40.2% and 26.2%,
respectively. Sales volume for human hepatitis B immunoglobulin and
human rabies immunoglobulin products decreased, due to a temporary
shortage of vaccines needed to generate each type of raw material,
by 0.5% and 5.1%, respectively.
Gross profit for 2009 was $86.4
million, up 164.1% from $32.7
million in 2008. Gross margin was 72.6% in 2009, as compared
to 70.0% in the prior year. The increase in gross profit and margin
were primarily due to the consolidation of Dalin operations, an
increase in the ASP across the products and management's ability to
maintain efficiencies in the production process.
Total operating expenses in the full year 2009 increased 102.0%
to $25.0 million, versus $12.4 million in the prior year period. As a
percentage of sales revenue, total expenses decreased to 21.0% for
the full year 2009 from 26.5% in 2008.
Selling expenses increased 59.5% to $3.5
million from $2.2 million in
2008. The dollar increase in selling expenses was primarily due to
the consolidation of Dalin's selling activities, increased
marketing efforts to increase direct sales to new hospitals, and
expansion of the sales force in Qianfeng to expand into new sales
territories.
General and administrative ("G&A") expenses rose 120.2% to
$19.8 million. As a percentage of
sales, G&A expenses decreased to 16.6% in 2009 from 19.2% for
full year 2008. The dollar increase in G&A expenses was mainly
due to an increase in the administrative salary and employee
benefit costs, higher depreciation and amortization expenses and
professional service charge in connection with the Dalin
acquisition. The Company incurred $62,281 in non- cash stock-based compensation
expense, as compared to $1.3 million
for the full year 2008.
Research and development expenses in 2009 increased 42.5% to
$1.7 million, or 1.4% of total
revenues, as compared to $1.2
million, or 2.5% of total revenue, in 2008. The dollar
increase was primarily due to the consolidation of Dalin and
increased costs from continuing clinical trials on new products
during the 2009 period.
Total net other expenses in the full year 2009 were $33.3 million, as compared to $0.4 million in the prior year, primarily
reflecting a charge related to change in the fair value of warrant
liabilities and higher interest expenses in 2009. The Company
recognized a loss of $29.6 million
related to change in the fair value of warrant liabilities. No such
charge was required in 2008. Net interest expense increased to
$3.9 million for the full year 2009
from $0.4 million in 2008, primarily
due to higher interest expense related to financing in the
acquisition of Dalin, as well as the interest accrued to Qianfeng's
strategic investors.
Provision for income taxes increased 128.7% to $10.5 million in 2009, from $4.6 million in 2008. The effective tax rate for
2009 was 37.4%, as compared to 23.1% in 2008. The increase in
effective tax rate was due to the $29.6
million non-cash expense incurred in 2009 that is not
deductible under PRC tax law, resulting in an overstated effective
tax rate.
GAAP net income attributable to controlling interest in 2009 was
$1.3 million, as compared to net
income attributable to controlling interest of $12.0 million in 2008. Diluted earnings per share
were $0.07 as compared to earnings
per share of $0.56 a year ago.
Non-GAAP adjusted net income for 2009 was $31.3 million or $1.38 per diluted share, an increase of 135% from
$13.3 million, or $0.62 per diluted share for the full year 2008.
Non-GAAP adjusted net income and diluted earnings per share in 2009
exclude $29.6 million charge related
to change in the fair value of derivative liabilities, non-cash
employee compensation expenses, and adding back interest related to
the convertible notes under the if-converted method.
Financial Condition
As of December 31, 2009, the
Company had $53.8 million in cash and
cash equivalents, approximately $44.4
million in working capital, and a current ratio of 1.9x.
Total shareholder's equity for the fiscal year ended on
December 31, 2009 was $50.5 million, as compared to $37.8 million at the end of 2008. The Company
generated $50.3 million in net cash
from operating activities in 2009 as compared to $20.0 million in 2008.
The Company believes that it has sufficient funds to support its
strategic growth outlook, including capital expenditure plans of
approximately $15 million in 2010 to
expand the plasma collection network, both for new constructions
and for the scale up existing collection stations, and upgrading
the fractionation facility in Qianfeng.
Recent Developments
On February 2, 2010, China
Biologic appointed Dr. Xiangmin Cui
to serve as an independent member of its board of directors, as the
Chairman of the Compensation Committee, and as a member on the
Audit and Nominating Committees. Dr. Cui filled the vacancy left by
Dr. Gan's January 8, 2010 resignation
to dedicate more time to her other professional activities.
On March 1, 2010, China Biologic's
special committee of independent directors appointed by the
Company's board of directors in the wake of the recent allegations
against certain directors and an employee of the Company has
retained O'Melveny & Myers LLP, an international law firm, to
advise the special committee and to assist in the investigation of
the allegations.
2010 Guidance and Business Outlook
China Biologic expects 2010 revenue to be in the range between
$142 million and $149 million. This
guidance assumes only organic growth and does not include and
excludes acquisitions or approval for the construction of new
plasma collection stations. The guidance does not assume any
material price or volume increases during 2010.
The Company expects 2010 adjusted net income to be in the range
of $34 million to $36 million,
excluding any non-cash charge related to change in the fair value
of derivative liabilities and stock-based compensation expense, and
any adjustments in the U.S. federal income tax provision in 2010
related to the expiration of the look-through exception for Subpart
F income on December 31, 2009.
As a matter of policy, the Company does not intend to update
this guidance during the year.
Mr. Zhao added, "Through the dedication and commitment of our
hard working employees, we have been able to successfully increase
our presence in the plasma-based biopharmaceutical product market
in China. We estimate our current
market share is at approximately 18%. We plan to continue our
marketing efforts to increase public awareness of plasma donation,
as well as provide appropriate nutritional supplement compensation
to plasma donor, and apply for the construction of additional
plasma collection stations."
"With our aggressive research and development efforts in the
past few years, Human Prothrombin Complex Concentrate and Human
Coagulation Factor VIII have successful completed clinical trials
and have submitted applications to the SFDA for official production
permit and product certification. The Company looks forward to SFDA
approval of these products in the second half of 2010 and expects
to launch the commercial production of the products in late 2010 or
early 2011. We believe that the addition of these two new products
will broaden our product portfolio and improve our mix, enhance the
Company's competitive position and maximize the yield from our
current plasma supply."
Conference Call
China Biologic will host a conference call at 9:00 a.m. EDT on Wednesday, March 24, 2010, to discuss the fourth
quarter 2009 and year-end financial results. To participate in the
conference call, please dial the following number five to ten
minutes prior to the scheduled conference call time: 877- 409-5468.
International callers should dial +1-702-894-2400. The pass code
for the call is 64404888. If you are unable to participate in the
call at this time, a replay will be available for 14 days starting
on Wednesday, March 24, 2010 at
11:00 a.m. EDT. To access the replay,
dial 800-642-1687, international callers should dial
+1-706-645-9291. The conference pass code is 64404888.
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures that
exclude non- cash compensation expenses related to options granted
to employees and directors under the Company's 2008 Equity
Incentive Plan and changes in the fair value of derivative
liabilities, including warrants and derivative instruments
(including the conversion option) embedded in the Company's Senior
Secured Convertible Notes. To supplement the Company's condensed
consolidated financial statements presented on a GAAP basis, the
Company has provided non- GAAP financial information excluding the
impact of this item in this release. The Company's management
believes that these non-GAAP measures provide investors with a
better understanding of how the results relate to the Company's
historical performance. A reconciliation of the adjustments to GAAP
results appears in the table accompanying this press release. This
additional non-GAAP information is not meant to be considered in
isolation or as a substitute for GAAP financials. The non-GAAP
financial information that the Company provides also may differ
from the non-GAAP information provided by other companies.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect
majority-owned subsidiaries, Shandong Taibang Biological Products
Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its
equity investment in Xi'an Huitian Blood Products Co., Ltd., is
currently the largest non-state-owned plasma- based
biopharmaceutical company in China. The Company is a fully integrated
biologic products company with plasma collection, production and
manufacturing, research and development, and commercial operations.
The Company's plasma- based biopharmaceutical products are
irreplaceable during medical emergencies, and are used for the
prevention and treatment of various diseases. The Company sells its
products to hospitals and other healthcare facilities in
China. Please see the Company's
website http://www.chinabiologic.com for additional
information.
Safe Harbor Statement
This release may contain certain "forward-looking statements"
relating to the business of China Biologic Products, Inc. and its
subsidiaries. All statements, other than statements of historical
fact included herein are "forward-looking statements," including
statements regarding: the achievability of the financial guidance
provided by the management; the success of the R&D pipeline
projects, SFDA approval and commercial launch of new products; the
Company's ability to build new or expand existing plasma collection
stations; the Company's ability to achieve its commercial
objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of
non-historical information. These forward-looking statements are
often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, and involve known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov). All
forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by
these factors. Other than as required under the securities laws,
the Company does not assume a duty to update these forward-looking
statements.
- FINANCIAL TABLES FOLLOW -
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
FOR THE THREE MONTHS AND FISCAL-YEAR ENDED DECEMBER, 2009 AND 2008
Three Months Ended Three Months Ended
December 31, 2009 December 31, 2008
Net Diluted Net Diluted
Net Income (Loss) Diluted EPS Income EPS Income EPS
Adjusted Net Income - Non GAAP $11,069,396 $0.44 $3,233,097 $0.15
Non-cash employee compensation(1) $0.00 $0.00 27,926 $0.00
Loss in fair value of derivative
liabilities(2) $14,695,101 $0.59 $0.00 $0.00
Interest of Convertible Notes(3) $144,892 $0.01 $0.00
Net Income attributable to
controlling interest $(3,770,597) $(0.17) $3,205,171 $0.15
Weighted average number of
shares - diluted 24,947,251 21,556,342
Fiscal Year Ended Fiscal Year Ended
December 31, 2009 December 31, 2008
Net Diluted Net Diluted
Net Income (Loss) Diluted EPS Income EPS Income EPS
Adjusted Net Income - Non GAAP $31,255,377 $1.38 $13,297,398 $0.62
Non-cash employee compensation(1) $62,281 $0.00 $1,311,727 $0.06
Loss in fair value of derivative
liabilities(2) $29,626,189 $1.31 $0.00 $0.00
Interest of Convertible Notes(3) $302,010 $0.01
Net Income attributable to
controlling interest $1,264,897 $0.07 $11,985,671 $0.56
Weighted average number of
Shares 22,644,342 21,556,342
(1) Non-cash compensation expenses related to options granted to employees
and directors under the Company's 2008 Equity Incentive Plan
(2) Adoption of a new accounting rule effective January 1, 2009 requires
changes in the fair value of derivative liabilities to be recognized
in earnings each quarter.
(3) Interest of Convertible Notes is added back to net income attributable
to controlling interest using the if-converted method.
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
FOR THE THREE MONTHS AND TWELVE MONTHS ENDED DECEMBER 31, 2009 AND 2008
(Unaudited)
Three months ended Twelve months ended
December 31, December 31,
2009 2008 2009 2008
REVENUES $37,628,272 $13,176,396 $118,998,155 $46,751,160
COST OF REVENUES 10,284,313 4,315,499 32,621,908 14,040,602
GROSS PROFIT 27,343,959 8,860,897 86,376,247 32,710,558
OPERATING EXPENSES
Selling
expenses 1,215,663 426,733 3,529,242 2,212,073
General and
administrative
expenses 4,810,277 3,240,133 19,807,123 8,996,220
Research and
development
expenses 564,606 501,842 1,662,690 1,166,494
Total
operating
expenses 6,590,546 4,168,708 24,999,055 12,374,787
INCOME FROM
OPERATIONS 20,753,413 4,692,189 61,377,192 20,335,771
OTHER EXPENSES
(INCOME)
Equity in
income of
unconsolidated
affiliate (586,076) (175,231) (566,984) (175,231)
Change in fair
value of
derivative
liabilities 14,695,101 0 29,626,189 0
Other income -
related party (97,447) 0 (97,447) 0
Interest
expense, net 1,950,711 381,028 3,930,249 373,497
Other expense,
net (14,257) 141,123 358,699 251,390
Total other
expenses,
net 15,948,032 346,920 33,250,706 449,656
INCOME BEFORE
PROVISION FOR INCOME
TAXES AND
NONCONTROLLING
INTEREST 4,805,381 4,345,269 28,126,486 19,886,115
PROVISION FOR INCOME
TAXES 2,965,782 159,462 10,513,100 4,596,603
NET INCOME BEFORE
NONCONTROLLING
INTEREST 1,839,599 4,185,807 17,613,386 15,289,512
Less: Net income
attributable to
noncontrolling
interest 5,610,194 980,636 16,348,489 3,303,841
NET INCOME
ATTRIBUTABLE TO
CONTROLLING INTEREST (3,770,595) 3,205,171 1,264,897 11,985,671
OTHER COMPREHENSIVE
INCOME:
Foreign
currency
translation
adjustments 174,304 151,152 523,906 2,144,091
COMPREHENSIVE INCOME $(3,596,301) $3,356,323 $1,788,803 $14,129,762
BASIC EARNINGS PER
SHARE:
Weighted
average number
of shares 22,486,993 21,434,942 21,754,911 21,434,942
Earnings per
share $(0.17) $0.15 $0.06 $0.56
DILUTED EARNINGS PER
SHARE:
Weighted
average number
of shares 22,486,993 21,556,342 22,644,342 21,556,342
Earnings per
share $(0.17) $0.15 $0.07 $0.56
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
AS OF DECEMBER 31, 2009 AND 2008
ASSETS
December 31, December 31,
2009 2008
CURRENT ASSETS:
Cash and cash
equivalents $53,843,951 $8,814,616
Accounts receivable, net
of allowance for
doubtful accounts of
$1,254,955 and
$1,268,052 as of
December 31, 2009 and
2008, respectively 1,767,076 313,087
Accounts receivable -
related party 222,617 0
Dividend receivable 0 147,256
Other receivables 2,186,441 356,957
Inventories, net of
allowance for obsolete
of $519,333 and $0 as
of December 31, 2009
and 2008, respectively 35,132,724 14,949,196
Prepayments and deferred
expense 1,299,125 614,704
Deferred tax assets 1,053,771 0
Total current
assets 95,505,705 25,195,816
PLANT AND EQUIPMENT, net 28,873,413 19,299,364
OTHER ASSETS:
Investment in
unconsolidated
affiliate 6,627,355 6,533,977
Refundable deposit for
potential acquisition 0 14,181,800
Prepayments - non-
current 3,223,960 955,874
Intangible assets, net 21,180,322 1,002,561
Goodwill 12,425,589 0
Total other
assets 43,457,226 22,674,212
Total assets $167,836,344 $67,169,392
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable $3,701,843 $2,481,889
Notes payable 48,598 29,340
Short term loans - bank 4,474,350 0
Short term loans -
holder of
noncontrolling interest 3,652,500 773,277
Other payables and
accrued liabilities 19,246,814 3,962,931
Other payable - related
parties 3,086,940 0
Accrued interest -
holder of
noncontrolling interest 2,068,526 0
Distribution payable to
holder of
noncontrolling interest 587 3,252,354
Customer deposits 3,868,577 1,091,792
Taxes payable 8,774,079 4,060,010
Investment payable 2,195,365 3,275,501
Total current liabilities 51,118,179 18,927,094
OTHER LIABILITIES:
Other payable - land use
right 323,687 325,390
Notes payable, net of
discount of $8,464,380
as of December 31, 2009 89,760 0
Long term loan - bank,
net of current
maturities 0 5,868,000
Derivative liability -
conversion option 19,960,145 0
Fair value of derivative
instruments 12,701,262 0
Total other
liabilities 33,074,854 6,193,390
Total
liabilities 84,193,033 25,120,484
COMMITMENTS AND CONTINGENCIES
EQUITY:
Common stock, $0.0001 par value, 100,000,000 shares
authorized,
23,056,442 and 21,434,942 shares
issued and outstanding at
December 31, 2009 and
2008, respectively 2,305 2,143
Additional paid-in-capital 22,517,077 10,700,032
Statutory reserves 17,414,769 6,989,801
Retained earnings 5,302,605 15,392,253
Accumulated other
comprehensive income 5,276,791 4,752,885
Total shareholder s' equity 50,513,547 37,837,114
NONCONTROLLING INTEREST 33,129,764 4,211,794
Total equity 83,643,311 42,048,908
Total liabilities and
shareholder s' equity $167,836,344 $67,169,392
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2009 AND 2008
2009 2008
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income attributable to
controlling interest $1,264,897 $11,985,671
Net income attributable to
noncontrolling interest 16,348,489 3,303,841
Consolidated net income 17,613,386 15,289,512
Adjustments to reconcile
net income to cash
provided by operating
activities:
Depreciation 2,709,623 1,088,155
Amortization 3,358,532 61,095
Loss on disposal of
equipment 224,548 214,663
Recovery of bad
debt previously
reserved (31,826) (56,462)
Allowance for bad
debt - accounts
receivable 18,737 0
Allowance for bad
debt - other
receivables and
prepayments 280,796 560,668
Allowance for
obsolete
inventories 519,333 0
Deferred tax assets (1,053,124) 0
Impairment of
assets 0 415,873
Stock based
compensation 62,281 1,311,727
Change in fair
value of warrant
liabilities 29,626,189 0
Amortization of
deferred note
issuance cost 247,199 0
Amortization of
discount on
convertible notes 100,253 0
Equity in income of
unconsolidated
affiliate (566,984) (175,231)
Change in operating
assets and
liabilities:
Notes receivable 0 43,245
Accounts receivable (1,707,714) 81,980
Accounts receivable
- related party 197,284 0
Other receivables (1,744,794) (33,462)
Other receivables -
related party 0 1,442
Inventories (12,456,975) (4,695,495)
Prepayments and
deferred expenses (248,794) (459,019)
Accounts payable (58,467) (376,527)
Other payables and
accrued
liabilities 7,058,773 2,658,552
Accrued interest -
holder of
noncontrolling
interest 2,068,526 0
Customer deposits 274,768 653,514
Taxes payable 3,809,437 3,585,237
Contingent
liability 0 (149,428)
Net cash provided
by operating
activities 50,300,987 20,020,039
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired through
acquisition 11,946,933 0
Proceeds from dividend
receivable 384,087 0
Payments made for
acquisition (10,373,854) 0
Payments made for
unconsolidated affiliate (3,225,420) (3,171,300)
Purchase of plant and
equipment (1,873,371) (4,033,667)
Additions to intangible
assets (2,106,203) (83,259)
Proceeds from sale of
equipment 36,771 73,641
Prepayments for potential
acquisition 0 (14,181,800)
Refunds of advances on non-
current assets 1,174,346 0
Advances on non-current
assets (2,823,743) (270,119)
Net cash provided
by investing
activities (6,860,454) (21,666,504)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable 19,246 28,830
Proceeds from warrants
conversion 3,649,770 0
Proceeds from stock option
exercised 350,000 0
Proceeds from issuance of
convertible notes 8,967,516 0
Repayments of former
shareholders loan in
acquiring company (2,841,302) 0
Proceeds from short term
loans - bank 13,517,442 0
Payments on short term
loans - bank (18,355,572) (720,750)
Repayment of non-
controlling shareholder
loan (772,803) 0
Proceeds from long term
loan-bank 0 5,766,000
Distribution paid to
noncontrolling interest
shareholders (2,969,372) (288,300)
Net cash provided
by financing
activities 1,564,925 4,785,780
EFFECTS OF EXCHANGE RATE CHANGE IN
CASH 23,877 665,268
INCREASE IN CASH 45,029,335 3,804,583
CASH and CASH EQUIVALENTS, beginning
of year 8,814,616 5,010,033
CASH and CASH EQUIVALENTS, end of
year $53,843,951 $8,814,616
SUPPLEMENTAL DISCLOSURE OF CASH FLOW
INFORMATION
Income taxes paid $8,021,981 $1,523,867
Interest paid (net of
capitalized interest) $1,131,271 $108,170
Non-cash investing and
financing activities:
Unpaid investment in
unconsolidated
affiliate $0 $3,218,565
Reclassification of
warrant liability to
paid-in capital upon
warrants conversion $6,306,275 $0
Convertible notes
exercised $2,187,330 $0
Distribution paid by
offsetting accounts
receivable - related
party $944,036 $0
Distribution paid in
exchange of holder of
noncontrolling
interest loan $3,665,250 $0
Distribution paid by
offsetting loan and
interest due from
holder of
noncontrolling
interest $4,647,924 $0
Net assets acquired
with prepayments made
in prior periods $14,250,492 $78,905
Net assets acquired
with unpaid investment $2,850,098 $0
Plant and equipment
acquired with
prepayments made in
prior periods $2,296,113 $0
Land use right acquired
with prepayments made
in prior periods $146,610 $0
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Tel: +86-538-6202206
Email: IR@chinabiologic.com
Web: http://www.chinabiologic.com
Investor Relations Contact:
Ms. Lei Huang, Account Manager
CCG Investor Relations
Phone: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
SOURCE China Biologic Products, Inc.